{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T16:04:19Z","timestamp":1795190659641,"version":"4.10.3"},"reference-count":41,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Extramedullary disease (EMD) is associated with an inferior prognosis and lower response rates to conventional multiple myeloma (MM)\u2013directed therapies compared to MM without EMD. A deeper understanding of the molecular landscape and underlying drivers of EMD is essential to identify potential targets for novel therapeutic strategies. To address this, we performed whole-exome sequencing on EMD tumor tissue from 18 unique patients and bone marrow aspirates (BMAs) from 20 patients at the time of EMD development. Notably, paired EMD and BMA samples were collected from 6 patients at the point of EMD diagnosis, allowing for direct comparison of molecular profiles. Our analysis revealed a near-universal presence of mutations within the MAPK pathway in EMD samples (94%), compared to BMAs (60%; odds ratio, 10.7; P = .02; q &amp;lt; 0.1). Additionally, mutations in established driver genes (NRAS, KRAS, and BRAF) were common and frequently clonal, suggesting their central role in EMD pathogenesis. We also identified alterations in genes associated with cell adhesion and migration (ROBO1, ROBO2, and FAT1) and the SWI\/SNF complex and epigenetic regulators (ARID1A, KMT2C, KMT2D, and EP300), although these were predominantly subclonal. Furthermore, we frequently detected biallelic alterations in the tumor suppressor genes MAX (22%), a binding partner for MYC, and CDKN2C (17%). Genomic complexity was significantly higher in EMD samples than BMAs, as evidenced by increased tumor mutational burden and the enrichment of 1q gain\/amplifications. These findings underscore the distinct molecular profile of EMD compared to BMA and highlight the genomically complex and heterogeneous nature of extramedullary disease in MM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016619","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T16:09:10Z","timestamp":1747238950000},"page":"3979-3987","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Novak","sequence":"additional","affiliation":[{"name":"2Hematology Data Science, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Howe","sequence":"additional","affiliation":[{"name":"2Hematology Data Science, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3860-4830","authenticated-orcid":false,"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[{"name":"3Department of Cancer Biology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[{"name":"2Hematology Data Science, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"3","key":"2025081210064162200_bib1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2025081210064162200_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"2025081210064162200_bib3","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025081210064162200_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"2025081210064162200_bib5","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"2025081210064162200_bib6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ajh.27023","article-title":"Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma","volume":"98","author":"Zanwar","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2025081210064162200_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025081210064162200_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J"},{"issue":"14","key":"2025081210064162200_bib9","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025081210064162200_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"2","key":"2025081210064162200_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"2025081210064162200_bib12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","article-title":"Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors","volume":"38","author":"Jelinek","year":"2024","journal-title":"Leukemia"},{"issue":"2","key":"2025081210064162200_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","article-title":"Comprehensive characterization of cancer driver genes and mutations","volume":"173","author":"Bailey","year":"2018","journal-title":"Cell"},{"issue":"19","key":"2025081210064162200_bib14","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-22-3209","article-title":"Multiomic mapping of acquired chromosome 1 copy number and structural variants to identify therapeutic vulnerabilities in multiple myeloma","volume":"29","author":"Boyle","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025081210064162200_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood.2023022295","article-title":"RAS\/RAF landscape in monoclonal plasma cell conditions","volume":"144","author":"Schavgoulidze","year":"2024","journal-title":"Blood"},{"issue":"33","key":"2025081210064162200_bib16","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025081210064162200_bib17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2025081210064162200_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.2024024869","article-title":"RASping myeloma genomics","volume":"144","author":"Paiva","year":"2024","journal-title":"Blood"},{"issue":"14","key":"2025081210064162200_bib19","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.2022017789","article-title":"A phase 2 clinical trial of combined BRAF\/MEK inhibition for BRAFV600E-mutated multiple myeloma","volume":"141","author":"Giesen","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025081210064162200_bib20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41408-024-01190-9","article-title":"Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma","volume":"14","author":"Nakamoto-Matsubara","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025081210064162200_bib21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4161\/cbt.28411","article-title":"The emerging roles of ARID1A in tumor suppression","volume":"15","author":"Wu","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"2025081210064162200_bib22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2025081210064162200_bib23","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ccell.2024.05.026","article-title":"IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma","volume":"42","author":"Bolomsky","year":"2024","journal-title":"Cancer Cell"},{"key":"2025081210064162200_bib24","doi-asserted-by":"crossref","first-page":"e10483","DOI":"10.7554\/eLife.10483","article-title":"Bromodomain inhibition of the transcriptional coactivators CBP\/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma","volume":"5","author":"Conery","year":"2016","journal-title":"eLife"},{"issue":"9","key":"2025081210064162200_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"2025081210064162200_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2643-3230.BCD-20-0164","article-title":"ROBO1 promotes homing, dissemination, and survival of multiple myeloma within the bone marrow microenvironment","volume":"2","author":"Bianchi","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2025081210064162200_bib27","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"16","key":"2025081210064162200_bib28","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1158\/1078-0432.CCR-15-2366","article-title":"Impact of genes highly correlated with MMSET myeloma on the survival of non-MMSET myeloma patients","volume":"22","author":"Wu","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025081210064162200_bib29","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1038\/s41467-018-07497-z","article-title":"ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-\u03b2 signalling","volume":"9","author":"Pinho","year":"2018","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"2025081210064162200_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/blood-2024-204341","article-title":"Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease","volume":"144","author":"Maclachlan","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025081210064162200_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-024-01131-6","article-title":"Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease","volume":"14","author":"Stork","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025081210064162200_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ccell.2020.04.016","article-title":"MAX functions as a tumor suppressor and rewires metabolism in small cell lung cancer","volume":"38","author":"Augert","year":"2020","journal-title":"Cancer Cell"},{"issue":"suppl 1","key":"2025081210064162200_bib33","first-page":"4347","article-title":"Role of MAX as a tumor suppressor driver gene in multiple myeloma","volume":"130","author":"Barrio Garcia","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025081210064162200_bib34","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/nar\/gkw1184","article-title":"MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2025081210064162200_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"2025081210064162200_bib36","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"suppl 16","key":"2025081210064162200_bib37","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1200\/JCO.2022.40.16_suppl.8055","article-title":"Myeloma developing regimens using genomics (MyDRUG) trial: results from the RAS mutation targeting arm","volume":"40","author":"Kumar","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025081210064162200_bib38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2024-198403","article-title":"Mezigdomide (MEZI) in novel-novel combinations for relapsed or refractory multiple myeloma (RRMM): preliminary results from the CA057-003 trial","volume":"144","author":"Costa","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025081210064162200_bib39","doi-asserted-by":"crossref","first-page":"10064","DOI":"10.1038\/s41598-018-28107-4","article-title":"A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation","volume":"8","author":"Castell","year":"2018","journal-title":"Sci Rep"},{"issue":"17","key":"2025081210064162200_bib40","doi-asserted-by":"crossref","first-page":"eabh3635","DOI":"10.1126\/sciadv.abh3635","article-title":"A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression","volume":"8","author":"Holmes","year":"2022","journal-title":"Sci Adv"},{"issue":"12","key":"2025081210064162200_bib41","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","article-title":"Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies","volume":"41","author":"Nicosia","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3979\/2404899\/blooda_adv-2025-016619-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3979\/2404899\/blooda_adv-2025-016619-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:12:30Z","timestamp":1755011550000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/15\/3979\/537300\/Extramedullary-myeloma-is-genomically-complex-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":41,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016619","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,12]]},"published":{"date-parts":[[2025,7,31]]}}}